| abstract |
1. The combination of the peptides Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala- Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 and Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe- Pro-Leu-Glu-Phe-OH or their salts or hydrates. ! 2. The combination according to claim 1, where the peptides are contained in combination in an amount of from 30% by weight to 70% by weight to 70% by weight to 30% by weight. ! 3. The combination according to claim 1 for use in medicine. ! 4. The use of the peptide Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala- Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 or a combination according to claim 1, 2, or 3 to obtain a pharmaceutical composition for the treatment and / or prevention of a malignant tumor, autoimmune diseases, fibrosis , inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and blood vessel diseases and metabolic diseases. ! 5. The use of the peptide according to claim 4, where the malignant tumor, autoimmune disease, fibrosis, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease or metabolic disease are selected from vasculitis and excessive angiogenesis in autoimmune diseases, systemic sclerosis , multiple sclerosis, Sjogren's syndrome, vascular deformities in the networks of blood and lymph vessels, DiGeorge syndrome, congenital hemorrhagic telangiectasia, cavernous heme ngiomy, cutaneous hemangioma, lymphatic vascular deformations, transplant arteriopathy, atherosclerosis, vascular anastomoses, adipose tissue in obesity, chronic allograft rejection, skin diseases, psoriasis, warts, allergic dermatitis, keloid scar, pyogenic granulomas, vesicant disease cap |